Bioventus Inc. (NYSE:BVS) CEO Sells $261,952.60 in Stock

Bioventus Inc. (NYSE:BVS) CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at approximately $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bioventus Trading Up 4.1 %

Shares of BVS stock opened at $10.11 on Friday. The business’s fifty day moving average price is $10.99 and its 200 day moving average price is $10.18. The firm has a market capitalization of $820.43 million, a PE ratio of -16.57 and a beta of 0.85. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.06. The company had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same period last year, the company posted $0.05 earnings per share. As a group, sell-side analysts forecast that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC raised its stake in shares of Bioventus by 13.8% during the 2nd quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock worth $150,000 after buying an additional 3,170 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in Bioventus during the 3rd quarter valued at about $42,000. Quest Partners LLC acquired a new position in Bioventus during the third quarter worth about $51,000. Quarry LP acquired a new position in Bioventus during the third quarter worth about $59,000. Finally, Covestor Ltd acquired a new stake in shares of Bioventus in the third quarter valued at approximately $69,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BVS has been the subject of several recent research reports. Craig Hallum increased their price target on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group boosted their price target on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.